CORCEPT THERAPEUTICS INC Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
CORCEPT THERAPEUTICS INC (CORT) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $419.79 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2024-02-15
- CORCEPT THERAPEUTICS INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $419.79M, a 74.08% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $241.15M, a 39.55% decline from fiscal 2021.
- CORCEPT THERAPEUTICS INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $398.94M, a 32.06% increase from fiscal 2020.
- CORCEPT THERAPEUTICS INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2020 was $302.09M, a 65.71% increase from fiscal 2019.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|
| 2023-12-31 | $419.79M 10-K · filed 2024-02-15 |
| 2022-12-31 | $241.15M 10-K · filed 2024-02-15 |
| 2021-12-31 | $398.94M 10-K · filed 2024-02-15 |
| 2020-12-31 | $302.09M 10-K · filed 2023-02-28 |
| 2019-12-31 | $182.29M 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |